Recent groundbreaking research from Gladstone Institutes and UCSF has unraveled the intricate regulatory landscape that fine-tunes FOXP3 expression in immune cells. Published in the journal Immunity, this study offers unprecedented insights into how genetic switches govern the precise levels of FOXP3, thus controlling immune function with remarkable specificity. The findings not only elucidate why FOXP3 behaves differently in human versus mouse immune cells but also pave the way for innovative immune therapies targeting autoimmunity and cancer.

At the heart of this exploration lies the question: how is FOXP3 expression meticulously controlled? Regulatory T cells (Tregs), which act as immune brakes to prevent autoimmunity, rely on this gene to function correctly. Without FOXP3, Tregs fail, leading to unchecked immune reactions and severe autoimmune disorders in humans. Curiously, unlike mouse Tregs that express FOXP3 exclusively, human conventional T cells—typically pro-inflammatory—can transiently switch on FOXP3, a phenomenon that has long mystified immunologists.

To dissect this complexity, the research team employed expansive CRISPR gene-editing screens to examine 15,000 DNA regions flanking the FOXP3 gene. These regions contain cis-regulatory elements, akin to molecular dimmer switches, that adjust gene activity. Through systematic disruption of these sites in both mouse and human T cells, researchers composed the first functional map of the FOXP3 regulatory circuitry, revealing distinct dimmer switches in different immune cell types.

Crucially, the study revealed that in human regulatory T cells, multiple redundant enhancers collectively maintain sustained FOXP3 expression. This redundancy ensures resilience; removing any single enhancer results in only minor expression changes, highlighting a robust safeguard mechanism. By contrast, conventional T cells possess a more streamlined regulatory architecture, involving just two enhancers and a surprising inhibitory element—a genetic repressor—that acts as a molecular brake on FOXP3 activation.

This sophisticated regulatory circuit, described by first author Dr. Jenny Umhoefer, underscores a delicate interplay between ‘gas pedals’ (enhancers) and ‘brakes’ (repressors) that together orchestrate precise FOXP3 expression. To uncover what proteins orchestrate these switches, the scientists conducted a complementary genome-wide CRISPR screen targeting nearly 1,350 transcription factors and regulatory proteins. This approach identified key players that bind directly to FOXP3 enhancers and repressors, further refining the architecture of this gene regulatory network.

Utilizing ChIP-seq and other advanced genomic technologies, the team mapped protein-DNA interactions across the FOXP3 locus, linking regulatory proteins to specific enhancers and repressor elements. This integrative methodology enabled a comprehensive understanding of the molecular machinery that regulates FOXP3, transcending previous studies limited to isolated genomic elements. According to co-author Dr. Ansuman Satpathy, this represents an extraordinary step forward in connecting local DNA features to the transcriptional proteins governing gene expression.

One of the study’s most striking revelations was the resolution of the species-specific behavior of FOXP3 in conventional T cells. The researchers initially hypothesized that humans possess unique enhancers absent in mice, accounting for FOXP3 activation in human conventional T cells. Unexpectedly, mouse conventional T cells share the same enhancers, but differ in the presence of a robust repressor element that shuts off FOXP3. Disabling this repressor in mice unleashed FOXP3 expression in conventional T cells, effectively mimicking the human regulatory pattern.

This finding not only unravels the species divergence enigma but also offers profound evolutionary insights into how gene regulatory circuits adapt across organisms. It emphasizes the critical role of repressive elements, which have been largely overlooked compared to enhancers, in dictating gene expression patterns fundamental to immune cell identity and function.

Beyond basic science, these discoveries have exciting translational potential. A detailed map of FOXP3’s regulatory elements equips researchers with targets to finely manipulate regulatory T cell activity for therapeutic purposes. Enhancing FOXP3 expression could bolster regulatory T cells, offering relief in autoimmune diseases by tempering harmful inflammation. Conversely, dampening FOXP3 might unlock immune responses against tumors, empowering cancer immunotherapies by unleashing the full anti-cancer potential of T cells.

Dr. Alex Marson, who led the study, highlights how these newfound insights could accelerate precision cell engineering strategies. By distinguishing cell-type-specific gene control mechanisms, scientists can develop more targeted interventions that modulate immune responses with minimal off-target effects. This represents a paradigmatic shift towards rational therapies addressing immune-related diseases’ complexity with unprecedented specificity.

This research stands at the confluence of genomic technology and immunology, leveraging CRISPR’s immense power to probe gene regulation at an unprecedented scale and resolution. It exemplifies how functional genomics can unravel biological mysteries while informing therapeutic innovation, heralding a new era of molecular immune circuit engineering.

The work also reflects a collaborative triumph among leading institutions, including Gladstone Institutes, UCSF, Stanford, UC Berkeley, and ETH Zürich, supported by numerous prestigious funding agencies and foundations. As research continues, the comprehensive understanding of FOXP3 regulation is poised to drive breakthroughs in treating a spectrum of diseases rooted in immune dysregulation.

In summary, this landmark study illuminates the complex regulatory network controlling FOXP3 expression, revealing intricate enhancer and repressor dynamics that fine-tune immune function across species. It resolves a long-standing biological puzzle and opens exciting avenues for designing next-generation immunotherapies. Armed with these insights, the scientific community moves closer to precisely modulating the immune system’s brakes and accelerators to combat autoimmunity and cancer with sophistication and precision.

Subject of Research: Regulation of FOXP3 gene expression in immune cells and its implications for immune system balance, autoimmunity, and cancer.

Article Title: FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry

News Publication Date: November 13, 2025

Web References:

• DOI link
• Nobel Prize Summary 2025
• Gladstone Institutes

Image Credits: Michael Short/Gladstone Institutes

Keywords: Immune cells, T lymphocytes, Gene regulation, Transcription factors, CRISPRs, Epigenetics, Regulatory T cells, Autoimmunity, Autoimmune disorders, Cancer

The discovery of Tregs marks a monumental milestone in immunology, revealing a cellular system that delicately modulates immune activity to prevent harmful overreactions. Unlike traditional immune effector cells that activate defense responses, regulatory T cells act as guardians that suppress inappropriate immune activation. This prevents the immune system from launching attacks that could damage healthy tissues—an essential process for maintaining what scientists call “immune tolerance.” The underlying mechanisms discovered by Professor Sakaguchi demonstrate that the immune system is governed by a balance between activation and suppression, a dynamic seen in the interplay of Tregs and other immune cells.

Professor Sakaguchi’s research sheds light on how Tregs operate by modulating the behavior of other immune cells to prevent pathological inflammation. These regulatory cells inhibit the activity of autoreactive T cells—those that may mistakenly target self-antigens—and downregulate inflammatory responses that, if left unchecked, can lead to devastating autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. The insights into their development, signaling pathways, and suppressive functions have opened new frontiers in immunological research and therapeutic innovation.

One of the most compelling aspects of this discovery lies in its profound therapeutic implications. Understanding Tregs offers promising avenues for treating not only autoimmune diseases but also allergies, transplant rejection, and even cancer. By harnessing or modulating Treg activity, medical science can potentially fine-tune immune responses—either bolstering the immune attack against tumors and infections or dampening pathological autoimmunity. This dual potential underscores the importance of Professor Sakaguchi’s work as a foundational pillar in the future of immune-based treatments.

The journey to elucidate the function of regulatory T cells was a marathon of perseverance, collaboration, and innovation. Over many years, through meticulous experimentation and the integration of molecular biology, immunogenetics, and cellular immunology, Professor Sakaguchi and his colleagues mapped the complex signaling milieu that defines Treg development and suppressive function. Their work involved identifying specific molecular markers such as the transcription factor Foxp3, which serves as a signature of Tregs and is critical for their immunoregulatory roles. This multilayered understanding culminated in a framework that explains how immune tolerance is established and maintained.

Professor Sakaguchi emphasized that this discovery was made possible not only via scientific rigor but also through a broader societal support for fundamental research. Basic science, often undervalued in its immediate practical applications, was vindicated by this achievement, highlighting how curiosity-driven research can transform our grasp of human biology and catalyze medical progress. His success is a testament to the collaborative spirit among researchers, students, and institutions, particularly The University of Osaka and Kyoto University, where he conducted much of his work.

In his own words, Professor Sakaguchi expressed deep gratitude towards the scientific community and reiterated his commitment to fostering an environment where young researchers could pursue innovative basic research freely. He highlighted the critical role of mentorship, intellectual freedom, and resource availability in enabling breakthroughs that push the frontiers of science. By inspiring future generations to explore the intricate mysteries of life, he envisions a sustained legacy in immunological research and beyond.

The Nobel Prize recognition also resonates with broader implications for global health. Autoimmune diseases and allergies affect millions worldwide, imposing significant morbidity and economic burden. The identification of Tregs and their suppressive function provides a key to unlock targeted therapies that could alleviate these conditions. Moreover, with cancer therapies increasingly turning to immunomodulation, manipulating Tregs could either circumvent their inhibitory effect on anti-tumor immunity or be targeted to restore immune homeostasis after treatment.

Professor Atsushi Kumanogoh, President of The University of Osaka, also acknowledged the global impact of this discovery, affirming that it catalyzed a surge in research activities internationally. This advancement has spurred multidisciplinary explorations that extend from molecular immunology to clinical applications. The award stands as a symbol of the perseverance required for pioneering basic research and serves as encouragement to emerging scientists persevering through their own challenges.

The science behind regulatory T cells not only redefines immune paradigms but also bridges gaps between bench research and clinical science. Tregs represent a novel class of immune cells that have reshaped our understanding of immune tolerance and homeostasis. Their relevance continues to grow as new layers of their functionality and interaction networks are uncovered, promising exciting developments in immunotherapy, vaccine design, and the treatment of chronic inflammatory conditions.

In summary, Professor Shimon Sakaguchi’s Nobel-winning research has revealed the essential immunoregulatory role of Treg cells—a discovery that fundamentally changes how we perceive immune balance, disease mechanisms, and therapeutic possibilities. His work affirms the importance of patience, collaboration, and fundamental research as cornerstones of scientific advancement and human health.

The celebration of this Nobel Prize victory at The University of Osaka is not only a recognition of a singular scientific achievement but also a beacon illuminating the power of rigorous investigation and the pursuit of knowledge. As the scientific community celebrates this landmark discovery, the door opens wider for innovative treatments that could transform healthcare for autoimmune diseases, cancer, and beyond, offering hope to millions around the globe.

Subject of Research: Regulatory T cells (Tregs) and their role in immune suppression and tolerance.

Article Title: Nobel Prize Awarded to Professor Shimon Sakaguchi for Discovery of Regulatory T Cells, Revolutionizing Immunology

News Publication Date: October 6, 2023

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/f5a43c48-896d-4680-a64b-2d51019ee2b4/Rendition/low-res/Content/Public

Image Credits: The University of Osaka

Keywords: Life sciences, Immunology, Regulatory T Cells, Immune Suppression, Autoimmune Diseases, Immune Tolerance, Nobel Prize

At the forefront of NF-κB research, a collaborative review authored by Professors Alexander Hoffmann and Genhong Cheng from UCLA alongside Nobel laureate David Baltimore from Caltech offers an all-encompassing synthesis of NF-κB’s multifaceted mechanisms and therapeutic potentials. Published in the open-access journal Immunity & Inflammation on September 4, 2025, this authoritative review dissects NF-κB’s canonical and non-canonical activation pathways, the nuanced layers of transcriptional regulation, and the clinical implications of targeting this pathway in diverse diseases.

The canonical NF-κB signaling pathway is predominantly activated by external stimuli such as microbial infection or inflammatory cues. Upon engagement of pattern recognition receptors like Toll-like receptors (TLRs), or cytokine receptors such as TNFR1, and antigen receptors including T cell receptors (TCR) and B cell receptors (BCR), a cascade ensues that culminates in the assembly and activation of the inhibitor of κB kinase (IKK) complex. This complex phosphorylates the inhibitory protein IκBα, marking it for degradation and thereby liberating NF-κB dimers to translocate into the nucleus where they drive transcription of target genes. This pathway is tightly modulated by sophisticated negative feedback loops through proteins like IκB and A20, ensuring balanced immune responses. Dysregulation here can precipitate severe conditions, such as cytokine storms triggered by hyperactive TLR4 signaling or tumorigenesis linked to chronic IKKβ activation.

In juxtaposition, the non-canonical NF-κB pathway unfolds with markedly slower kinetics and principally governs adaptive immune functions including lymphoid organ development and B cell survival. Activated by a limited cohort of tumor necrosis factor receptor superfamily members, this axis hinges on the NF-κB-inducing kinase (NIK) to drive processing of the p100 precursor into p52, shaping a distinct NF-κB dimer composition. The non-canonical route is intricately regulated, with aberrations frequently implicated in malignancies and autoimmune pathologies. Persistent NIK stabilization is a hallmark of several B cell lymphomas, while sustained BAFF signaling prolongs autoreactive B cell lifespan in systemic lupus erythematosus, illustrating the clinical significance of this pathway’s homeostasis.

Importantly, these seemingly discrete signaling routes intersect and engage in molecular cross-talk, with NIK influencing canonical IKK complexes and canonical NF-κB activity inducing expression of components like p100 and A20, creating a highly interconnected regulatory network. This integration ensures that NF-κB responses are finely tuned to cellular context and stimulus type, harmonizing immune activation and developmental processes in a tightly controlled manner.

Transcriptional regulation by NF-κB is exceedingly dynamic and context-specific. The functional outcomes depend heavily on the composition of NF-κB dimers—combinations of RelA, RelB, c-Rel, p50, and p52 subunits—which differ in DNA-binding specificity and interactions with chromatin remodelers and co-regulators. Furthermore, various post-translational modifications on NF-κB subunits provide an additional regulatory dimension, enabling rapid, reversible control of transcriptional activity. This complexity allows NF-κB to exert differential effects on gene expression, sometimes exhibiting opposing functions in inflammation and cell survival, underscoring the pathway’s duality in health and disease.

The pathological spectrum influenced by NF-κB is broad, encompassing chronic inflammatory disorders, oncogenesis, neurodegeneration, metabolic syndromes, cardiovascular diseases, and autoimmunity. Hoffmann and colleagues provide a detailed review of therapeutic modalities targeting NF-κB signaling, ranging from small-molecule inhibitors to biologics that dampen upstream receptor activation or kinase activity. Despite significant progress, these interventions are constrained by side effects such as immunosuppression, development of drug resistance, inadvertent promotion of tumorigenesis, and toxicity. Such challenges highlight the imperative for next-generation strategies with improved precision.

Emerging therapeutic avenues aimed at selectively modulating NF-κB subunits or harnessing novel technologies like proteolysis-targeting chimeras (PROTACs), gene editing tools, nanomedicine delivery systems, and combinatorial immunotherapies represent promising directions for overcoming existing limitations. Tailored approaches that consider the context-dependent nature of NF-κB signaling could revolutionize treatment paradigms in inflammatory and neoplastic diseases by maximizing efficacy while minimizing adverse outcomes.

Looking ahead, the authors emphasize the necessity of integrating cutting-edge technologies including multi-omics analytics, high-resolution imaging, and artificial intelligence-driven data interpretation to dissect NF-κB’s spatiotemporal regulation at molecular and systemic scales. Advancements in these areas will facilitate unprecedented insights into how NF-κB orchestrates complex cellular responses in vivo, paving the way for rational and personalized therapeutic interventions.

Echoing the vision of Professor David Baltimore, who sadly passed away shortly after this publication, the translation of foundational NF-κB research into precision medicine holds promise for tailored combinatorial therapies that address individual patient heterogeneity. This personalized approach aims to harness the full therapeutic potential of NF-κB modulation while mitigating risks, aspiring to transform patient outcomes across a spectrum of immune-related and malignant diseases.

This comprehensive review not only honors the legacy of Prof. Baltimore but sets a new standard in our understanding of NF-κB’s centrality to immunology and beyond. It serves as a critical resource for researchers and clinicians seeking to unravel the intricate biology of this master regulator and to innovate effective therapeutic strategies that can alleviate human suffering caused by NF-κB dysregulation.

Subject of Research: Not applicable

Article Title: NF-κB: Master Regulator of Cellular Responses in Health and Disease

News Publication Date: 4-Sep-2025

References:
DOI: 10.1007/s44466-025-00014-0

Image Credits:
Prof. Alexander Hoffmann and Prof. Genhong Cheng from the University of California, U.S.

Keywords:
Immunology; Signal transduction; NF kappa B pathway; Inflammation; Immune response; Autoimmune disorders; Cancer research; Gene regulation; Drug development

The Notch signaling pathway plays a central role in cellular differentiation processes, governing how progenitor cells commit to specialized immune functions. Among its many roles, Notch signaling is essential for the generation and maturation of T-cells — immune cells pivotal for recognizing and eradicating pathogens and tumor cells. However, laboratory activation of this pathway has historically been constrained due to difficulty in replicating the complex cell-cell interactions required to trigger Notch receptors effectively. Traditional methods involving flat, two-dimensional cultures failed to mimic the intricate synapse formations necessary for robust signaling.

Addressing this technical bottleneck, the research team led by George Daley, Dean of Harvard Medical School and Co-Founder of the Stem Cell and Regenerative Biology Program at Boston Children’s Hospital, engineered a novel class of soluble Notch agonists. These synthetic ligands are designed to function in liquid suspension cultures, circumventing the limitations of surface-bound activation. This approach enables more scalable and clinically relevant production of T-cells, poised to meet the increasing demand for adoptive cellular immunotherapies.

A key technological enabler for this breakthrough was the Rosetta protein design platform, developed by David Baker’s laboratory. This computational tool, which earned Baker the 2024 Nobel Prize in Chemistry for its capacity to design proteins from first principles, allowed researchers to create entirely new protein structures with tailored geometries and binding modalities. Rubul Mout, a Boston Children’s research fellow and former Baker lab member, spearheaded the screening of a diverse panel of multivalent Notch ligands, each with distinct spatial arrangements and modes of receptor engagement.

The critical insight from the study was that trans-binding orientations of these ligands induced the most potent Notch receptor clustering at the cell-cell interface. This receptor clustering forms a specialized signaling hub analogous to natural immune synapses, amplifying Notch activation and downstream signaling cascades. Such receptor synapse enhancement is pivotal since Notch activation requires juxtacrine signaling—direct contact between adjacent cells—which the soluble agonists ingeniously replicate in a fluid, scalable system.

Daley emphasizes the broad potential unlocked by this platform: “AI-driven protein design is a broadly enabling platform technology that we’ve exploited to develop a synthetic molecule facilitating T-cell manufacture for clinical use and enhancing immune responses when delivered in vivo.” This includes applications not only in ex vivo T-cell expansion but also in situ modulation of immune cells to potentiate tumor clearance, representing a significant stride toward precision immunoengineering.

Further highlighting the translational power of this technology, Mout elaborates, “Being able to activate Notch signaling opens up lots of opportunities in immunotherapy, vaccine development, and immune cell regeneration.” His ongoing efforts focus on engineering synthetic proteins that not only bridge T-cells and cancer cells but also bolster T-cell cytotoxic functions while neutralizing the immunosuppressive tumor microenvironment—one of the major barriers to effective cancer immunotherapy. This integrated approach aims to produce more durable and potent immune responses in patients.

The implications of this work extend far beyond T-cell biology. Notch signaling governs critical decisions in numerous developmental and regenerative contexts, including stem cell maintenance, neuronal differentiation, and tissue homeostasis. The ability to precisely modulate this pathway using designer soluble ligands opens avenues for regenerative medicine and therapeutic interventions targeting a range of diseases with aberrant Notch activity.

Technically, the success of this approach hinges on the rational design of protein ligands with customized valency and geometry to mimic the natural spatial constraints necessary for robust receptor engagement. The research leveraged advanced AI algorithms to iteratively refine ligand structures, optimizing binding affinity and synapse formation. This reflects a new paradigm in synthetic biology, where computational design accelerates the creation of bespoke molecular therapies with unprecedented specificity.

The engineered Notch agonists exhibit robust activity in liquid suspension cultures, a critical feature facilitating their integration into existing bioprocessing workflows for T-cell manufacturing. By enabling scalable expansion without the need for complex surface coatings or feeder cell layers, this technology promises to lower production costs and increase accessibility of T-cell-based therapies worldwide.

Moreover, experimental validation demonstrated that these synthetic ligands can stimulate T-cell development ex vivo and enhance immune functions in vivo, offering a dual modality of action. This versatility makes them attractive candidates not only for cell therapy manufacturing but also for direct therapeutic delivery, potentially in the form of injectable biologics that reprogram immune cells within patients.

Looking forward, the team envisions extending this computational protein design framework to develop multifunctional synthetic ligands capable of orchestrating diverse immune pathways. Combining AI-driven precision design with deep immunological insights could revolutionize immunotherapy, enabling tailored modulation of immune circuits to overcome diseases previously deemed intractable.

The publication of this work in Cell marks a milestone in interdisciplinary science, marrying computational biology, protein engineering, and immunology to solve a fundamental challenge in therapeutic cell production. As AI and machine learning continue to evolve, their integration into biomedical research promises to unlock novel therapeutic strategies and usher in a new era of biologic drug development.

This transformative research not only sheds light on the biology of Notch signaling in immune cells but also exemplifies how next-generation technologies can rapidly translate basic science discoveries into clinical innovations. With immunotherapy at the forefront of personalized medicine, synthetic Notch agonists crafted by AI hold immense promise for improving patient outcomes in cancer and beyond.

Subject of Research: Activation of Notch signaling pathway via engineered synthetic ligands for T-cell development and immunotherapy enhancement.

Article Title: Design of Soluble Notch Agonists that Drive T Cell Development and Boost Immunity

News Publication Date: 1-Aug-2025

Web References:
DOI:10.1016/j.cell.2025.07.009

Keywords: Notch pathway; Computational biology; Signaling pathways; T cell signaling; Immunotherapy; Artificial intelligence